Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1635 1654 1675
This examiner grants 55% of resolved cases
Thea D' Ambrosio is an examiner in Tech Center 1600 and Art Unit 1635 with 499 resolved cases. Her allowance rate is 55.3%, and the interview lift is 56.1%. This 56.1% lift suggests that interviews correlate with a higher likelihood of a grant compared to the 55.3% baseline rate. This lift is a factor for practitioners to consider during prosecution.
The median days to allowance is 1188, which defines the pendency for the cases she has handled. An interview is a strategy to consider in Tech Center 1600. The 1188-day timeline provides an expectation for the duration of successful applications. For the 499 resolved cases, the data indicates that direct communication is a factor in her examination process. These metrics are the primary indicators for Art Unit 1635. The prosecution environment is defined by these specific data points.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18517548 | PEPTIDE HAVING INDEPENDENTLY STABILIZED HYDROPHOBIC ALPHA HELIX, PEPTIDE COMPLEX COMPRISING SAME AND USES THEREOF | Non-Final OA | UIF (University Industry Foundation), Yonsei University |
| 17271991 | COMPOSITIONS AND METHODS FOR PROTEIN DETECTION | Final Rejection | Syngenta Participations AG |
| 18030250 | COMPOSITIONS AND METHODS OF TREATING A PI3K MEDIATED DISEASE | Final Rejection | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. |
| 17631934 | AGENT FOR PREVENTING OR TREATING MILD COGNITIVE IMPAIRMENT | Final Rejection | NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY |
| 18352101 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF WOUNDS | Final Rejection | Imperial College Innovations Limited |
| 17772526 | AN EXTRACELLULAR VESICLE | Final Rejection | Cambridge Enterprise Limited |
| 18272154 | TYPE I MEMBRANE PROTEINS HETERODIMERS AND METHODS OF USE THEREOF | Final Rejection | Thomas Jefferson University |
| 17279228 | GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | Final Rejection | TAKEDA PHARMACEUTICAL COMPANY LIMITED |
| 17416845 | NOVEL COMPOSITION | Final Rejection | ARECOR LIMITED |
| 17044706 | MEDICAL INFUSION PUMP SYSTEM FOR THE DELIVERY OF AN INSULIN COMPOUND | Non-Final OA | Arecor Limited |
| 18251534 | Combination Treatment of Cancer | Non-Final OA | Ares Trading S.A. |
| 17089220 | COMPOSITIONS AND METHODS FOR TREATMENT OR PREVENTION OF SKIN DISEASES AND DISORDERS WITH LEKTI | Final Rejection | Azitra Inc |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy